All In Biotech

Drug Trial Radar · NCT05707676

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors(MEETCD8-001)

A Phase I,Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors(MEETCD8-001)

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

40

Actual

Start

Nov 30, 2022

Primary completion

Dec 20, 2024

Study completion Dec 20, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I study designed to evaluate if LB4330, an anti-Claudin 18.2 and CD8 T cell activator fusion protein, is safe, tolerable and efficacious in participants with Advanced Solid Tumors

Conditions

  • Solid Tumor

Interventions

  • LB4330Drug

    LB4330

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTD/RP2DTime frame: up to study completion,approximately 24 months
  2. DLT occurrence and frequency (dose escalation phase)Time frame: The first period of LB4330 treatment (28 days for the first subject in the first dose group, 21 days for the rest subjects. If the administration is delayed, the DLT evaluation period should be extended to 7 days after the third administration)
  3. AE, SAE occurrence and frequency (according to NCI CTCAE 5.0)Time frame: up to 90 days following last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.